dd, 1H, ArH), 7. 73 (s, 1H, ArH), 7. 79 (d, 2H, ArH), 8. 45 (d, 1H, ArH). HR-MS: Calcd for C37H32N405612. 67, found 612. 24〇
[0066] 按照类似于实施例1-Ol的合成方法，选择适当的反应原料及中间体，即可分别制 得实施例1-02~1-06的衍生物。
[0067] 实施例 1-02 :
[0068] 4' -[ [2-丙基-4-甲基-6 (1-甲基苯并咪唑-2-基）-苯并咪唑-1-基]甲 基]-2-联苯羧酸（4-甲基噁唑-2 (3H)-酮-5-基）甲酯
[0069] 1H NMR (400MHz，CDCl3) δ : 〇· 90 (t，3H，CH3)，I. 65 (m，2H，CH2)，I. 92 (s，3H，CH3)，2 .26 (s, 3H, CH3), 2. 87 (q, 2H, CH2), 3. 95 (s, 3H, NCH3), 4. 92 (s, 2H, CH2), 7. 22 (m, 2H, ArH), 7 .28 (m, 1H, ArH), 7. 52 (dd, 1H, ArH), 7. 59 (d, 2H, ArH), 7. 68 (d, 2H, ArH), 7. 69 (d, 1H, ArH), 7. 72 (dd, 1H, ArH), 7. 73 (s, 1H, ArH), 7. 79 (d, 2H, ArH), 8. 01 (s, 1H, NH), 8. 45 (d, 1H, ArH). HR-MS:Calcd for C37H33N504611. 25, found 611. 34〇
[0070] 实施例 1-03 :
[0071] 4'-[[2-丙基-4-甲基-6 (I-甲基苯并咪唑-2-基）-苯并咪唑-I-基]甲 基]-2-联苯羧酸（4-甲基异噁唑-5 (2H)-酮-3-基）甲酯
[0072] 1H (400MHz, CDCl3) δ : 〇· 90 (t, 3H, CH3)，1. 65 (m, 2H, CH2)，1. 92 (s, 3H, CH3)，2 .05 (s, 1H, NH), 2. 43 (s, 3H, CH3), 2. 87 (q, 2H, CH2), 3. 95 (s, 3H, NCH3), 4. 92 (s, 2H, CH2), 7. 22 (m, 2H, ArH), 7. 28 (m, 1H, ArH), 7. 52 (dd, 1H, ArH), 7. 59 (d, 2H, ArH), 7. 68 (d, 2H, ArH), 7 .69 (d, 1H, ArH), 7. 72 (dd, 1H, ArH), 7. 73 (s, 1H, ArH), 7. 79 (d, 2H, ArH), 8. 45 (d, 1H, ArH). HR-MS:Calcd for C37H33N504611. 25, found 611. 42〇
[0073] 实施例 1-04 :
[0074] 4' _[ [2-丙基-4-甲基-6 (I-甲基苯并咪唑-2-基）-苯并咪唑-I-基]甲 基]-2-联苯羧酸（1-(乙氧羰基氧基））乙酯
[0075] 1H NMR(400MHz, CDCl3) δ :〇· 90(t, 3H, CH3), I. 29(t, 3H, CH3), I. 65(m, 2H, CH2), 1. 78 (d, 3H, CH3) I. 92 (s, 3H, CH3), 2. 87 (q, 2H, CH2), 3. 95 (s, 3H, NCH3), 4. 25 (q, 2H, CH2), 6. 61 (q, 1H, CH), 7. 22 (m, 2H, ArH), 7. 28 (m, 1H, ArH), 7. 52 (dd, 1H, ArH), 7. 59 (d, 2H, ArH), 7. 68 ( d, 2H, ArH), 7. 69 (d, 1H, ArH), 7. 72 (dd, 1H, ArH), 7. 73 (s, 1H, ArH), 7. 79 (d, 2H, ArH), 8. 45 (d ，1H, ArH) .HR-MS:Calcd for C37H36N405616. 27, found 616.31。
[0076] 实施例 1-05 :
[0077] 4' _[ [2-丙基-4-甲基-6 (I-甲基苯并咪唑-2-基）-苯并咪唑-I-基]甲 基]-2-联苯羧酸（1_(甲氧羰基氧基））丙酯
[0078] 1H NMR (400MHz，CDCl3) δ : 〇· 90 (t，6H，CH3)，1. 65 (m，2H，CH2)，1. 78 (d，3H，CH3)，1 .92 (s, 3H, CH3), 2. 03 (m, 2H, CH2), 3. 79 (s, 2H, CH2), 3. 95 (s, 3H, NCH3), 6. 43 (t, 1H, CH), 7. 22 (m, 2H, ArH), 7. 28 (m, 1H, ArH), 7. 52 (dd, 1H, ArH), 7. 59 (d, 2H, ArH), 7. 68 (d, 2H, ArH), 7 .69 (d, 1H, ArH), 7. 72 (dd, 1H, ArH), 7. 73 (s, 1H, ArH), 7. 79 (d, 2H, ArH), 8. 45 (d, 1H, ArH). HR-MS:Calcd for C37H36N405616. 27, found 616. 58〇
[0079] 实施例 1-06 :
[0080] 4' -[ [2-丙基-4-甲基-6 (I-甲基苯并咪唑-2-基）-苯并咪唑-I-基]甲 基]-2-联苯羧酸-4-羟甲基哌啶酯
[0081] 1H NMR(400MHz, CDCl3) δ :〇· 90(t, 3H, CH3), I. 65(m, 2H, CH2), I. 92(s, 3H, CH3), 2. 04 (m, 4H, CH2), 2. 46 (m, 4H, CH2), 2. 87 (t, 2H, CH2), 3. 65 (s, 1H, OH), 3. 95 (s, 3H, NCH3), 4. 60 (s, 2H, CH2), 5. 22 (m, 1H, CH), 7. 22 (m, 2H, ArH), 7. 28 (m, 1H, ArH), 7. 52 (dd, 1H, ArH), 7. 59 ( d, 2H, ArH), 7. 68 (d, 2H, ArH), 7. 69 (d, 1H, ArH), 7. 72 (dd, 1H, ArH), 7. 73 (s, 1H, ArH), 7. 79 (d, 2H, ArH)，8. 45 (d, 1H, ArH) · HR-MS:Calcd for C3SH39N503613. 31，found 613. 59〇
[0082] 实施例 1-07 :
[0083] 4' -[ [2-丙基-4-甲基-6 (I-甲基苯并咪唑-2-基）-苯并咪唑-I-基]甲 基]-2-联苯羧酸（（苯并噁唑-2 (3H)-酮）-6-基）甲酯
[0085] 试剂及反应条件：二氯甲烷，三乙胺，冰盐浴
[0086] 实验操作：在250mL三口瓶中加入3. 3g(0. 020mol)6-羟基苯并噁唑-2(3H)_酮， 加入30mL二氯甲烷溶解，加入3. llg(0. 031mol)三乙胺，冰盐浴下降温。取 881-(4-((6-溴-2-甲氧基喹啉基-3-基）（苯基）甲胺基）苯乙酮（1-〇2)溶于8〇11^二氯 甲烷溶液中，将该溶液滴入上述6-羟基苯并恶唑-2 (3H)-酮溶液中，冰盐浴下搅拌2小时， 升至室温，搅拌2小时，加入SOmL水，用二氯甲烷萃取，合并有机相，无水硫酸镁干燥，过滤， 蒸干溶剂，柱层析纯化得白色固体目标产物8. 2克，收率84. 1 %。
[0087] 1H NMR (400MHz，CDCl3) δ : 〇· 90 (t，3H，CH3)，1. 65 (m，2H，CH2)，1. 92 (s，3H，CH3)，2. 8 7 (t, 2H, CH2), 3. 95 (s, 3H, NCH3), 7. 16 (d, 1H, ArH), 7. 22 (m, 2H, ArH), 7. 25 (s, 1H, ArH), 7. 30 ( m, 1H, ArH), 7. 52 (dd, 1H, ArH), 7. 59 (d, 2H, ArH), 7. 68 (d, 2H, ArH), 7. 69 (d, 1H, ArH), 7. 72 (d d, 1H, ArH), 7. 73 (s, 1H, ArH), 7. 79 (d, 2H, ArH), 8. 06 (s, 1H, NH), 8. 35 (s, 1H, ArH), 8. 45 (d, I H, ArH). HR-MS:Calcd for C39H31N5046 3 3 . 69, found 633. 54〇
[0088] 按照类似于实施例1-07的合成方法，选择适当的反应原料及中间体，即可分别制 得实施例1-08~1-9的衍生物。
[0089] 实施例 1-08 :
[0090] 4' -[ [2-丙基-4-甲基-6 (1-甲基苯并咪唑-2-基）-苯并咪唑-1-基]甲 基]-2-联苯羧酸5-苯并-1，3-二噁戊烷酯
[0091] 1H NMR (400MHz，CDCl3) δ : 〇· 90 (t，3H，CH3)，1. 65 (m，2H，CH2)，1. 92 (s，3H，CH3)，2. 8 7 (t, 2H, CH2), 3. 95 (s, 3H, NCH3), 6. 06 (s, 2H, CH2), 6. 81 (d, 1H, ArH), 6. 89 (s, 1H, ArH), 6. 98 ( d, 1H, ArH), 7. 22 (m, 2H, ArH), 7. 30 (m, 1H, ArH), 7. 52 (dd, 1H, ArH), 7. 59 (d, 2H, ArH), 7. 68 (d ,2H, ArH), 7. 69 (d, 1H, ArH), 7. 72 (dd, 1H, ArH), 7. 73 (s, 1H, ArH), 7. 79 (d, 2H, ArH), 8. 45 (d ,1H, ArH). HR-MS:Calcd for C39H32N4046 20 . 24, found 620. 49〇
[0092] 实施例 1-09 :
[0093] 4' -[ [2-丙基-4-甲基-6 (I-甲基苯并咪唑-2-基）-苯并咪唑-I-基]甲 基]-2-联苯羧酸-5-茚满酯
[0094] 1H NMR(400MHz, CDCl3) δ :〇· 90(t, 3H, CH3), I. 65(m, 2H, CH2), I. 92(s, 3H, CH3), 1. 99 (m, 2H, CH2), 2. 76 (t, 4H, CH2), 2. 87 (t, 2H, CH2), 3. 95 (s, 3H, NCH3), 6. 96 (s, 1H, ArH), 7. 04 (d, 1H, ArH), 7. 22 (d, 2H, ArH), 7. 26 (d, 1H, ArH), 7. 30 (m, 1H, ArH), 7. 52 (dd, 1H, ArH), 7. 59 (d, 2H, ArH), 7. 68 (d, 2H, ArH),